MX2019014759A - Compuestos de azaindol como inhibidores de metiltransferasa de histona. - Google Patents

Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Info

Publication number
MX2019014759A
MX2019014759A MX2019014759A MX2019014759A MX2019014759A MX 2019014759 A MX2019014759 A MX 2019014759A MX 2019014759 A MX2019014759 A MX 2019014759A MX 2019014759 A MX2019014759 A MX 2019014759A MX 2019014759 A MX2019014759 A MX 2019014759A
Authority
MX
Mexico
Prior art keywords
compounds
histone methyltransferase
methyltransferase inhibitors
azaindole compounds
glp
Prior art date
Application number
MX2019014759A
Other languages
English (en)
Inventor
Yu Chul
Yu Ming
Zancanella Manuel
Li Zhe
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of MX2019014759A publication Critical patent/MX2019014759A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona ciertos compuestos tricíclicos angulares que son inhibidores de las metiltransferasas de histona G9a y/o GLP y, por lo tanto, que son útiles para el tratamiento de las enfermedades que se puedan tratar por medio de la inhibición de G9a y/o GLP, tales como cánceres y hemoglobinopatías (por ejemplo, beta-talasemia y la enfermedad de anemia drepanocítica). También se proporcionan composiciones farmacéuticas que contienen estos compuestos y procesos para la preparación de estos compuestos.
MX2019014759A 2017-06-09 2018-06-07 Compuestos de azaindol como inhibidores de metiltransferasa de histona. MX2019014759A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517410P 2017-06-09 2017-06-09
PCT/US2018/036521 WO2018226998A1 (en) 2017-06-09 2018-06-07 Azaindole compounds as histone methyltransferase inhibitors

Publications (1)

Publication Number Publication Date
MX2019014759A true MX2019014759A (es) 2020-02-12

Family

ID=62779058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014759A MX2019014759A (es) 2017-06-09 2018-06-07 Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Country Status (11)

Country Link
US (2) US11111243B2 (es)
EP (1) EP3634962B1 (es)
JP (1) JP7225125B2 (es)
CN (1) CN110997671A (es)
AR (1) AR112192A1 (es)
BR (1) BR112019025770A2 (es)
ES (1) ES2949402T3 (es)
IL (1) IL271066A (es)
MX (1) MX2019014759A (es)
TW (1) TW201920165A (es)
WO (1) WO2018226998A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114394971B (zh) * 2022-01-24 2023-01-31 云南大学 一种吲哚咔唑类化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3741801A (en) 2000-03-15 2001-09-24 Aventis Pharma Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
MX2009008798A (es) 2007-02-22 2009-08-24 Syngenta Participations Ag Derivados de iminipiridina y sus usos como microbicidas.
CN101945867A (zh) 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
BRPI0915273B1 (pt) 2008-11-11 2021-08-03 Je Il Pharmaceutical Co., Ltd Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação
AU2010303567B2 (en) * 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
US20130231360A1 (en) 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
US9168247B2 (en) * 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
TW201236880A (en) 2011-03-11 2012-09-16 Primax Electronics Ltd Sheet feeding apparatus
DK2937349T3 (en) * 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
ES2769648T3 (es) 2014-06-16 2020-06-26 Fundacion Para La Investig Medica Aplicada Nuevos compuestos como inhibidores duales de histona metiltransferasas y ADN metiltransferasasASAS
JP2018537450A (ja) 2015-11-16 2018-12-20 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada Dnaメチルトランスフェラーゼ阻害剤としての新規化合物

Also Published As

Publication number Publication date
US20180354947A1 (en) 2018-12-13
BR112019025770A2 (pt) 2020-06-23
WO2018226998A1 (en) 2018-12-13
ES2949402T3 (es) 2023-09-28
TW201920165A (zh) 2019-06-01
JP2020523315A (ja) 2020-08-06
JP7225125B2 (ja) 2023-02-20
IL271066A (en) 2020-01-30
EP3634962B1 (en) 2023-05-24
US11111243B2 (en) 2021-09-07
EP3634962A1 (en) 2020-04-15
CN110997671A (zh) 2020-04-10
US20210371417A1 (en) 2021-12-02
AR112192A1 (es) 2019-10-02

Similar Documents

Publication Publication Date Title
PH12017502203A1 (en) Tyrosine kinase inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
PH12018500423A1 (en) Inhibitors of ezh2
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
PH12015502028A1 (en) Ido inhibitors
NZ731696A (en) Method for treating cancer
MX2015008196A (es) Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2016010106A (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020005866A (es) Derivado de pirrolo(pirazolo)pirimidina como inhibidor de lrrk2.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
JOP20210034A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
SA520411303B1 (ar) مركبات ثلاثية الحلقات بوصفها مثبطات ناقلة ميثيل للهيستون
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019014759A (es) Compuestos de azaindol como inhibidores de metiltransferasa de histona.
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
WO2019006002A8 (en) Methods of treating cancer with small molecule nf-kb inhibitors
IN2014MU00815A (es)